April 29, 2020 / 11:43 AM / a month ago

BRIEF-ResTORbio And Adicet Bio Announce Merger Agreement To Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

April 29 (Reuters) - resTORbio, Inc.:

* RESTORBIO AND ADICET BIO ANNOUNCE MERGER AGREEMENT TO ADVANCE ALLOGENEIC GAMMA DELTA CAR-T CELL THERAPY TECHNOLOGY

* RESTORBIO, INC. - WELL CAPITALIZED INTO 2022 TO DEVELOP NOVEL CELL THERAPIES

* RESTORBIO, INC. - COMBINED COMPANY TO FOCUS ON ADICET’S TECHNOLOGY AND CONTINUE OPERATIONS AS “ADICET BIO”

* RESTORBIO, INC. - ADICET WOULD MERGE WITH A WHOLLY-OWNED SUBSIDIARY OF RESTORBIO IN AN ALL-STOCK TRANSACTION

* RESTORBIO, INC. - EQUITYHOLDERS OF ADICET WILL BECOME MAJORITY OWNERS (75%) OF RESTORBIO’S OUTSTANDING COMMON STOCK UPON CLOSE OF MERGER

* RESTORBIO, INC. - STOCKHOLDERS OF ADICET WILL RECEIVE SHARES OF NEWLY ISSUED RESTORBIO COMMON STOCK

* RESTORBIO, INC. - PARTIES ANTICIPATE THAT COMBINED COMPANY’S PRIMARY FOCUS WILL BE TO ADVANCE ADICET’S UNIQUE CELL THERAPY PLATFORM

* RESTORBIO, INC. - PARTIES ANTICIPATE THAT COMBINED COMPANY WILL CONTINUE DEVELOPMENT OF RTB101

* RESTORBIO, INC. - UPON COMPLETION OF MERGER, COMBINED COMPANY WILL OPERATE UNDER NAME ADICET BIO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below